Cassava Sciences Awarded NIH Research Grant for Simufilam
Cassava Sciences (SAVA) announced that it has been awarded a new $2.7 million research grant from the National Institutes of Health (NIH). The grant was awarded following a peer review of clinical and scientific data for simufilam, its drug candidate for Alzheimer's disease, and is intended to fund clinical readiness activities . . .
This content is for paid subscribers.
Impacting News May 12, 2021